ASBP

Business Context and Reporting Period

Company: Aspire Biopharma Holdings, Inc. (ASBP)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Aspire is an early-stage biopharmaceutical company developing sublingual delivery mechanisms for drugs and supplements (e.g., aspirin, caffeine). The company recently completed a reverse recapitalization and executed two reverse stock splits (1-for-40 in Jan 2026 and 1-for-30 in May 2026). All share data is retroactively restated.

Key Financial Metrics

Note: Gross margin is negative due to a $42,372 inventory write-off for obsolete goods.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded revenue for the first time in the current period ($63,104 for Q2), whereas there was no revenue in the comparable period of 2025. This follows the launch of "Buzz Bomb" caffeine products.
• Net Loss Reduction: Net loss decreased significantly to $(1.27M) for Q2 2026 from $(1.98M) in Q2 2025. The six-month loss decreased to $(4.49M) from $(17.92M) in the prior year.
• Operating Expenses:
  • Sales & Marketing: Increased to $1.22M (Q2) from $51k (Q2 2025) due to product launch and investor awareness campaigns.
  • General & Administrative: Increased to $970k (Q2) from $396k (Q2 2025), driven by professional fees.
  • Stock-Based Compensation: Decreased significantly year-over-year. Q2 2026 included $157,500 in stock-based comp, compared to $14.1M in the six months ended June 30, 2025 (related to the reverse recapitalization).
• Debt Extinguishment: The company recorded a gain of $1.35M on extinguishment of debt in Q2 2026, primarily due to the dismissal of a $1M legal claim by Srirama Associates, LLC, and the write-off of related liabilities.
• Liquidity: Cash balances surged from $1.0M at year-end 2025 to $12.2M at June 30, 2026, driven by financing activities.

Guidance, Outlook, and Risks

• Capital Raising: The company raised approximately $20M in Series A Convertible Preferred Stock in early 2026 (two tranches). It also maintains an Equity Line of Credit (ELOC) allowing for up to $100M in stock sales over 24 months.
• Acquisition Activity:
  • DCS Acquisition: On August 6, 2026 (subsequent event), the company closed the acquisition of Dura Driver Control Systems (DCS) for approximately $30M. Initial accounting is incomplete.
  • Financing: A $22.5M senior secured credit facility commitment was entered into to finance the DCS acquisition.
• Product Pipeline:
  • Aspirin: Clinical trials for high-dose sublingual aspirin concluded positively in Q3 2025. An FDA 505(b)(2) submission is planned for H1 2027.
  • Supplements: "Buzz Bomb" caffeine products are currently being sold online and at events.
• Risks & Contingencies:
  • Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing complex accounting areas related to the recapitalization.
  • Liquidity: While management believes current cash is sufficient for 12 months, the company remains in a development stage with an accumulated deficit of $31.7M.
  • Legal: A lawsuit regarding a $1M promissory note fee was dismissed with prejudice in June 2026, resulting in a gain on extinguishment.

Investor Verification Checklist

• Acquisition Accounting: Verify the final purchase price allocation and goodwill recognition for the DCS acquisition closed in August 2026, as initial accounting is incomplete.
• Internal Controls: Review the remediation plan for the ineffective disclosure controls and procedures identified in Item 4.
• Debt Structure: Confirm the terms and conversion triggers of the $20M Series A Convertible Preferred Stock and the $22.5M credit facility.
• Revenue Sustainability: Assess whether the $91k revenue in the first half of 2026 is recurring or driven by one-time sales (filing notes one customer accounted for 15% of revenue).
• Regulatory Status: Monitor the timeline for the FDA 505(b)(2) submission for the sublingual aspirin product, currently targeted for H1 2027.